MCID: FLR002
MIFTS: 54

Filariasis malady

Categories: Infectious diseases

Aliases & Classifications for Filariasis

Aliases & Descriptions for Filariasis:

Name: Filariasis 12 52 42 14 69
Disease Due to Superfamily Filarioidea 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1080
ICD9CM 35 125.9
MeSH 42 D005368
NCIt 47 C34611
UMLS 69 C0016085

Summaries for Filariasis

Disease Ontology : 12 A parasitic helminthiasis infectious disease that involves parasitic infection of the lymphatics and subcutaneous tissue by nematodes of the superfamily Filarioidea.

MalaCards based summary : Filariasis, also known as disease due to superfamily filarioidea, is related to loiasis and pulmonary eosinophilia. An important gene associated with Filariasis is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Albendazole and Ivermectin have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and t cells, and related phenotypes are hematopoietic system and immune system

Wikipedia : 71 Filariasis is a parasitic disease caused by an infection with roundworms of the Filarioidea type. These... more...

Related Diseases for Filariasis

Diseases related to Filariasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 327)
id Related Disease Score Top Affiliating Genes
1 loiasis 33.0 IFNG IL10 IL5
2 pulmonary eosinophilia 29.1 ALB IFNG IL10 IL6 TLR2 TLR9
3 mansonelliasis 29.0 ALB CCL5 CHIT1 CTLA4 IFNG IL10
4 dengue hemorrhagic fever 28.8 IFNG IL10 IL2 IL5 TLR2 TLR4
5 myiasis 28.8 IFNG IL10 IL2 IL6 TLR4 TNF
6 rheumatoid arthritis 28.0 CCL5 CTLA4 IFNG IL10 IL2 IL6
7 filarial elephantiasis 12.0
8 dirofilariasis 11.3
9 elephantiasis 11.2
10 lymphedema 11.2
11 onchocerciasis 11.2
12 podoconiosis 11.1
13 setariasis 10.7
14 dipetalonemiasis 10.7
15 malaria 10.3
16 gastroschisis abdominal wall defects, included 10.2 IFNG IL5
17 paralytic poliomyelitis 10.2 IFNG IL2 TLR4
18 multiple epiphyseal dysplasia due to collagen 9 anomaly 10.2 IFNG IL2 IL5
19 oral cavity carcinoma in situ 10.2 IFNG IL10 TLR2
20 actinic keratosis 10.2 IL10 IL2 IL5
21 acute gonococcal prostatitis 10.2 CTLA4 IFNG IL5
22 oropharynx cancer 10.2 IFNG IL10 IL2
23 pyridoxal 5'-phosphate-dependent epilepsy 10.2 IL10 TNF
24 denys-drash syndrome 10.2 CTLA4 IFNG IL10
25 reproductive system disease 10.2 IL10 IL6 TLR2
26 premature menopause 10.2 IL5 IL6 TLR2
27 janus kinase-3 deficiency 10.2 CTLA4 IFNG IL2
28 steatitis 10.2 IL2 TNF
29 hydrocele 10.2
30 asymptomatic neurosyphilis 10.2 IFNG IL10
31 tubular renal disease-cardiomyopathy syndrome 10.2 IL10 TNF
32 childhood choriocarcinoma of the testis 10.1 IL10 IL2 TLR9
33 spotted fever 10.1 TLR2 TLR4 TNF
34 autoimmune hemolytic anemia 10.1 CTLA4 IFNG IL2
35 aseptic meningitis 10.1 TLR2 TLR4 TNF
36 cataract, total congenital 10.1 IFNG IL5 IL6
37 congenital hypothyroidism 10.1 IL10 TLR2 TNF
38 autosomal dominant robinow syndrome 3 10.1 CTLA4 IL10 IL2
39 hemangioma of spleen 10.1 IFNG IL5 IL6
40 polyarteritis nodosa 10.1 IFNG TLR2 TLR4 TLR9
41 ciliary discoordination, due to random ciliary orientation 10.1 ALB IFNG IL10
42 astrocytoma 10.1 IL10 IL5 TNF
43 lepromatous leprosy 10.1 IFNG IL10 IL6
44 dentin caries 10.1 TLR2 TLR4 TNF
45 joubert syndrome 18 10.1 CTLA4 IL10 IL2
46 rosacea 10.1 ALB IFNG IL10
47 chronic thromboembolic pulmonary hypertension 10.1 CTLA4 IFNG IL10 IL2
48 endogenous depression 10.1 IL2 TLR2 TNF
49 pericholangitis 10.1 TLR2 TLR4 TNF
50 isolated growth hormone deficiency 10.1 ALB IFNG TLR4

Graphical network of the top 20 diseases related to Filariasis:



Diseases related to Filariasis

Symptoms & Phenotypes for Filariasis

MGI Mouse Phenotypes related to Filariasis:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.27 TLR6 TLR9 TNF CCL5 CTLA4 IFNG
2 immune system MP:0005387 10.25 CCL5 CHIT1 CTLA4 IFNG IL10 IL2
3 digestive/alimentary MP:0005381 10.24 IL10 IL2 IL5 IL6 TLR2 TLR4
4 homeostasis/metabolism MP:0005376 10.17 CTLA4 IFNG IL10 IL2 IL5 IL6
5 endocrine/exocrine gland MP:0005379 10.08 IL2 IL6 TLR2 TNF ALB CTLA4
6 liver/biliary system MP:0005370 10.02 ALB CTLA4 IFNG IL10 IL2 IL5
7 integument MP:0010771 9.91 CTLA4 IFNG IL10 IL6 TLR2 TLR4
8 neoplasm MP:0002006 9.81 TNF ALB IFNG IL10 IL2 IL5
9 muscle MP:0005369 9.8 ALB IFNG IL10 IL6 TLR2 TLR4
10 reproductive system MP:0005389 9.56 IFNG IL10 IL2 IL5 IL6 TLR4
11 respiratory system MP:0005388 9.28 CTLA4 IFNG IL10 IL2 IL5 IL6

Drugs & Therapeutics for Filariasis

Drugs for Filariasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 44)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Albendazole Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 54965-21-8 2082
2
Ivermectin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 70288-86-7 6474909 46936176
3
Diethylcarbamazine Approved, Vet_approved Phase 4,Phase 2,Phase 1 90-89-1 3052
4
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 564-25-0 54671203
5
Praziquantel Approved, Vet_approved Phase 4 55268-74-1 4891
6
Azithromycin Approved Phase 4,Phase 2 83905-01-5 55185 53477736 447043
7 Anthelmintics Phase 4,Phase 2,Phase 3,Phase 1
8 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
9 Antimitotic Agents Phase 4,Phase 2,Phase 3,Phase 1
10 Antiparasitic Agents Phase 4,Phase 2,Phase 3,Phase 1
11 Antiprotozoal Agents Phase 4,Phase 2,Phase 3,Phase 1
12 Lipoxygenase Inhibitors Phase 4,Phase 2,Phase 1
13 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
14 Antimalarials Phase 4,Phase 3,Phase 2
15 Anticonvulsants Phase 4
16
Glycerol Approved, Experimental Phase 3 56-81-5 753
17
Petrolatum Approved Phase 3 8009-03-8
18 Disinfectants Phase 3
19 Eusol Phase 3
20 Protective Agents Phase 3
21 Sodium hypochlorite Phase 3
22 Milbemycin Phase 3,Phase 2
23 Vitamins Phase 3
24
Rifampin Approved Phase 2 13292-46-1 5458213 5381226
25 Artemisinine Phase 2
26 Artemisinins Phase 2
27
Dihydroartemisinin Phase 2 71939-50-9 6918483
28
Piperaquine Phase 2 4085-31-8 5079497
29 Antibiotics, Antitubercular Phase 2
30 Antitubercular Agents Phase 2
31 Cytochrome P-450 CYP3A Inducers Phase 2
32 Nucleic Acid Synthesis Inhibitors Phase 2
33 Antibodies Phase 2
34 Antibodies, Monoclonal Phase 2
35 Immunoglobulins Phase 2
36 Imatinib Mesylate Phase 2 123596
37 Protein Kinase Inhibitors Phase 2
38
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
39
Suramin Approved 145-63-1 5361
40
Mebendazole Approved, Vet_approved 31431-39-7 4030
41
Piperazine Approved, Vet_approved 110-85-0 4837
42 Piperazine citrate
43 Citrate Nutraceutical
44
Citric Acid Nutraceutical, Vet_approved 77-92-9 311

Interventional clinical trials:

(show top 50) (show all 55)
id Name Status NCT ID Phase
1 Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in Mali Completed NCT02784743 Phase 4
2 Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis Completed NCT01593722 Phase 4
3 Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection Completed NCT02005653 Phase 4
4 Twice Yearly Treatment for the Control of LF Recruiting NCT03036059 Phase 4
5 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) Not yet recruiting NCT03014167 Phase 4
6 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis Not yet recruiting NCT02734186 Phase 4
7 Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy Not yet recruiting NCT03052998 Phase 4
8 Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis Withdrawn NCT01903057 Phase 4
9 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed NCT02509481 Phase 2, Phase 3
10 An RCT to Evaluate the Effect of a New Skin Care Regimen on SBF in Those With Podoconiosis Completed NCT02839772 Phase 3
11 Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection Completed NCT00790998 Phase 3
12 A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in Sri Lanka Not yet recruiting NCT02929134 Phase 3
13 A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India Not yet recruiting NCT02929121 Phase 3
14 A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali Not yet recruiting NCT02927496 Phase 3
15 Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana Not yet recruiting NCT02078024 Phase 3
16 Effect of Albendazole Dose on Treatment of Lymphatic Filariasis Completed NCT00511004 Phase 2
17 Doxycycline to Treat Mansonella Perstans Infection in Patients With and Without Lymphatic Filariasis Completed NCT00340691 Phase 2
18 Effect of Albendazole Dose on Clearance of Filarial Worms Completed NCT00339417 Phase 2
19 Effect of Albendazole Dose on Clearance of Filarial Worms Completed NCT00375583 Phase 2
20 Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study Completed NCT02511353 Phase 2
21 Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection Completed NCT00300768 Phase 2
22 Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness Completed NCT00127504 Phase 2
23 Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana Completed NCT02281643 Phase 2
24 Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa Active, not recruiting NCT01975441 Phase 2
25 Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis Active, not recruiting NCT01111305 Phase 2
26 Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa Not yet recruiting NCT02644525 Phase 2
27 Pediatric Pharmacokinetics And Safety Study Of Moxidectin Withdrawn NCT01035619 Phase 2
28 First in Man Clinical Trial of Emodepside (BAY 44-4400) Recruiting NCT02661178 Phase 1
29 Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE) Active, not recruiting NCT02845713 Phase 1
30 Exhaled NO Testing in Filariasis Completed NCT01628497
31 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India Completed NCT01629771
32 Research for Elim of Filariasis Completed NCT00145223
33 Research for Elimination of Lymphatic Filariasis (ICIDR) Completed NCT00406627
34 Interaction Between HIV and Lymphatic Filariasis Completed NCT00295698
35 Medical Implications of Coinfection With Malaria and Filariasis Parasites Completed NCT00471666
36 Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination Completed NCT01586169
37 Evaluation of Antibacterial Soap for Treatment of Lymphedema in a Filariasis-Endemic Area Completed NCT00139100
38 Changes in HIV Viral Load in Patients Undergoing Treatment for Filariasis Completed NCT00344279
39 Promoting Consistent Shoe Use Among Children At High Risk for Podoconiosis Completed NCT01160523
40 Immune Response Regulation in People Infected Concurrently With Malarial and Filarial Parasites Completed NCT00341666
41 Safety and Efficacy of Drug Combinations Against Triple Infections Completed NCT01050517
42 Community Directed Treatment of Soil-Transmitted Helminths Among Young Children in Zambia Completed NCT00349323
43 Study of Patients With Strongyloides Stercoralis Infection Completed NCT00001245
44 Epidemiology and Control of Mansonella Perstans Infection in Uganda Completed NCT00215280
45 Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis Recruiting NCT02899936
46 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast) Recruiting NCT02032043
47 Effect of Filarial Infection on Immune Responses in Latent Tuberculosis Recruiting NCT01547884
48 Host Response to Infection and Treatment in Filarial Diseases Recruiting NCT00001230
49 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Active, not recruiting NCT01905423
50 Lymphatic Filariasis (LF) in Ivory Coast Active, not recruiting NCT02974049

Search NIH Clinical Center for Filariasis

Cochrane evidence based reviews: filariasis

Genetic Tests for Filariasis

Anatomical Context for Filariasis

MalaCards organs/tissues related to Filariasis:

39
Breast, Testes, T Cells, B Cells, Endothelial, Kidney, Prostate

Publications for Filariasis

Articles related to Filariasis:

(show top 50) (show all 702)
id Title Authors Year
1
Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa. ( 28056015 )
2017
2
On the Thermal Stability of the Diethylcarbamazine-Fortified TableA Salt Used in the Control of Lymphatic Filariasis. ( 27397435 )
2016
3
Correction: Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania. ( 27564060 )
2016
4
Assessing Lymphatic Filariasis Data Quality in Endemic Communities in Ghana, Using the Neglected Tropical Diseases Data Quality Assessment Tool for Preventive Chemotherapy. ( 27028010 )
2016
5
Mathematical modelling of lymphatic filariasis elimination programmes in India: required duration of mass drug administration and post-treatment level of infection indicators. ( 27624157 )
2016
6
Congenital filariasis caused by Setaria bidentata (Nematoda: Filarioidea) in the red brocket deer (Mazama americana). ( 27788338 )
2016
7
Global elimination of lymphatic filariasis. ( 28012944 )
2016
8
Using Community-Level Prevalence of Loa loa Infection to Predict the Proportion of Highly-Infected Individuals: Statistical Modelling to Support Lymphatic Filariasis and Onchocerciasis Elimination Programs. ( 27906982 )
2016
9
Surveillance for transmission of lymphatic filariasis in Colombo and Gampaha districts of Sri Lanka following mass drug administration. ( 27816936 )
2016
10
Giant Scrotal Hydrocele and Bilateral Leg Lymphedema as Clinical Manifestation of Chronic Lymphatic Filariasis. ( 27840360 )
2016
11
Bilateral Testicular Metastases and Filariasis in Prostatic Adenocarcinoma. ( 28017535 )
2016
12
Programmatic Use of Molecular Xenomonitoring at the Level of Evaluation Units to Assess Persistence of Lymphatic Filariasis in Sri Lanka. ( 27196431 )
2016
13
Current Epidemiological Assessment of Bancroftian Filariasis in Tanga Region, Northeastern Tanzania. ( 28050171 )
2016
14
Elimination of lymphatic filariasis. ( 27492040 )
2016
15
Successful Control of Soil-Transmitted Helminthiasis in School Age Children in Burkina Faso and an Example of Community-Based Assessment via Lymphatic Filariasis Transmission Assessment Survey. ( 27163294 )
2016
16
A Rare Case of Ovarian Filariasis in Abidjan. ( 27313932 )
2016
17
Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis. ( 26996237 )
2016
18
Lymphatic Filariasis Elimination in American Samoa: Evaluation of Molecular Xenomonitoring as a Surveillance Tool in the Endgame. ( 27802280 )
2016
19
Further evidence of the cross-reactivity of the Binax NOWAr Filariasis ICT cards to non-Wuchereria bancrofti filariae: experimental studies with Loa loa and Onchocerca ochengi. ( 27151313 )
2016
20
Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study. ( 28012943 )
2016
21
Breast Filariasis Diagnosed by Real Time Sonographic Imaging: A Case Report. ( 27110331 )
2016
22
Historic accounts of Mansonella parasitaemias in the South Pacific and their relevance to lymphatic filariasis elimination efforts today. ( 26972389 )
2016
23
MOSQUITO IDENTIFICATION AND MOLECULAR XENOMONITORING OF LYMPHATIC FILARIASIS IN SELECTED ENDEMIC AREAS IN GIZA AND QUALIOUBIYA GOVERNORATES, EGYPT. ( 27363044 )
2016
24
Global programme to eliminate lymphatic filariasis: progress report, 2015. ( 27758091 )
2016
25
Mapping is a prerequisite for elimination of filariasis and effective targeting of filarial 'hot spots'. ( 27413817 )
2016
26
The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000-2014). ( 27388873 )
2016
27
Harmful traditional healing practices in the treatment of lymphatic filariasis. ( 27297275 )
2016
28
Can Lymphatic Filariasis Be Eliminated by 2020? ( 27765440 )
2016
29
Identification of immunodiagnostic antigens for cerebrospinal filariasis in horses by western blot analysis. ( 27073332 )
2016
30
Sustaining Progress towards NTD Elimination: An Opportunity to Leverage Lymphatic Filariasis Elimination Programs to Interrupt Transmission of Soil-Transmitted Helminths. ( 27416062 )
2016
31
Central nervous system filariasis masquerading as a glioma: case report. ( 28009239 )
2016
32
Intravitreal Filariasis: The Accidental Traveler. ( 26885575 )
2016
33
Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania. ( 27070786 )
2016
34
Subcutaneous filariasis in India- Possible indication of human Dirofilariasis. ( 27004586 )
2016
35
Chemical composition, toxicity and non-target effects of Pinus kesiya essential oil: An eco-friendly and novel larvicide against malaria, dengue and lymphatic filariasis mosquito vectors. ( 26995063 )
2016
36
Economic Costs and Benefits of a Community-Based Lymphedema Management Program for Lymphatic Filariasis in Odisha State, India. ( 27573626 )
2016
37
Understanding the relationship between prevalence of microfilariae and antigenaemia using a model of lymphatic filariasis infection. ( 27198217 )
2016
38
Epitope mapping of Brugia malayi ALT-2 and the development of a multi-epitope vaccine for lymphatic filariasis. ( 26892175 )
2016
39
Evaluation of Lymphatic Filariasis and Onchocerciasis in Three Senegalese Districts Treated for Onchocerciasis with Ivermectin. ( 27926918 )
2016
40
Investment success in public health: An analysis of the cost-effectiveness and cost-benefit of the Global Programme to Eliminate Lymphatic Filariasis. ( 27956460 )
2016
41
The Impact of Lymphatic Filariasis Mass Drug Administration Scaling Down on Soil-Transmitted Helminth Control in School-Age Children. Present Situation and Expected Impact from 2016 to 2020. ( 27992424 )
2016
42
Evaluating the Burden of Lymphedema Due to Lymphatic Filariasis in 2005 in Khurda District, Odisha State, India. ( 27548382 )
2016
43
I'-Cadinene, Calarene and I'-4-Carene from Kadsura heteroclita essential oil as novel larvicides against malaria, dengue and filariasis mosquitoes. ( 27151483 )
2016
44
Unusual presentation of filariasis as an abscess: A case report. ( 27011444 )
2016
45
Determinants of parasite drug resistance in human lymphatic filariasis. ( 27858056 )
2016
46
Doubts over India's deadline to defeat lymphatic filariasis. ( 27301812 )
2016
47
Scope of detectability of circulating antigens of human lymphatic filarial parasite Wuchereria bancrofti with smaller amount of serum by Og4C3 assay: its application in lymphatic filariasis elimination programme. ( 27876997 )
2016
48
Filariasis in Mandible and Maxilla: A Rare Entity-First Report of a Case. ( 27875706 )
2016
49
DILEMMAS OF COMMUNITY-DIRECTED MASS DRUG ADMINISTRATION FOR LYMPHATIC FILARIASIS CONTROL: A QUALITATIVE STUDY FROM URBAN AND RURAL TANZANIA. ( 27470198 )
2016
50
An asymptomatic inguinal swelling: Lymphatic filariasis. ( 27279316 )
2016

Variations for Filariasis

Expression for Filariasis

Search GEO for disease gene expression data for Filariasis.

Pathways for Filariasis

Pathways related to Filariasis according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 CCL5 CHIT1 CTLA4 IFNG IL10 IL2
2
Show member pathways
13.67 CCL5 IFNG IL10 IL2 IL5 IL6
3
Show member pathways
13.46 CCL5 IL10 IL2 IL5 IL6 TLR1
4
Show member pathways
13.38 CCL5 IFNG IL10 IL2 IL5 IL6
5
Show member pathways
13.28 CCL5 IL10 IL2 IL5 IL6 TNF
6
Show member pathways
13.28 IFNG IL2 TLR1 TLR2 TLR4 TLR6
7
Show member pathways
13.09 CCL5 IL6 TLR1 TLR2 TLR4 TLR6
8
Show member pathways
12.95 CTLA4 IFNG IL10 IL2 IL5 IL6
9
Show member pathways
12.91 CCL5 IFNG IL2 IL6 TLR2 TLR4
10
Show member pathways
12.89 CCL5 IFNG IL10 IL2 IL6 TLR1
11
Show member pathways
12.8 IL2 IL6 TLR1 TLR2 TLR4 TLR6
12
Show member pathways
12.72 TLR1 TLR2 TLR4 TLR6 TLR9 TNF
13
Show member pathways
12.68 IFNG IL10 IL2 IL5 IL6 TLR2
14
Show member pathways
12.65 IFNG IL10 IL2 IL6 TNF
15 12.58 IL2 IL6 TLR2 TLR4
16
Show member pathways
12.55 CTLA4 IFNG IL10 IL2 IL5 IL6
17
Show member pathways
12.48 TLR1 TLR2 TLR4 TLR6
18
Show member pathways
12.46 ALB CCL5 IFNG IL2 IL6 TNF
19 12.45 CCL5 CTLA4 IFNG IL10 IL2 TLR1
20
Show member pathways
12.44 IFNG IL5 IL6 TLR2 TNF
21
Show member pathways
12.37 IFNG IL10 TLR2 TLR4 TNF
22
Show member pathways
12.37 IL6 TLR1 TLR2 TLR4 TLR6 TLR9
23
Show member pathways
12.33 IFNG IL10 IL2 IL5 IL6
24
Show member pathways
12.32 IFNG IL6 TLR4 TNF
25
Show member pathways
12.29 IFNG IL10 IL2 IL5 IL6 TNF
26
Show member pathways
12.28 IFNG IL6 TLR1 TLR2 TLR4 TLR6
27 12.25 IFNG IL6 TLR1 TLR2 TLR4 TLR6
28 12.2 TLR1 TLR2 TLR4 TLR6 TLR9
29
Show member pathways
12.15 IL2 IL5 TLR1 TLR2 TLR4 TLR6
30 12.14 IFNG IL2 IL6 TLR4 TNF
31 12.14 IFNG IL10 IL2 IL5 IL6 TNF
32 12.06 IFNG IL10 IL6 TLR1 TLR2 TLR4
33
Show member pathways
12.05 IFNG IL6 TLR1 TLR2 TLR4 TLR6
34 12.03 IFNG IL10 IL6 TLR2 TLR4 TNF
35 11.98 CCL5 CTLA4 IFNG IL6 TLR2 TLR4
36 11.97 IL10 IL6 TNF
37 11.96 TLR1 TLR2 TLR4 TLR6 TLR9
38 11.95 CCL5 IL6 TNF
39 11.93 IFNG IL10 IL2 IL5 TNF
40 11.92 IFNG IL2 IL5 IL6
41 11.91 IFNG IL6 TLR4
42 11.9 IL5 IL6 TNF
43
Show member pathways
11.9 CTLA4 IFNG IL2 IL5 TNF
44 11.89 IL10 IL6 TLR4 TNF
45 11.88 IFNG IL10 IL2 IL6 TLR9 TNF
46 11.84 IFNG IL6 TLR4
47 11.83 IFNG IL10 IL2 IL6
48 11.8 CCL5 IL5 IL6 TNF
49
Show member pathways
11.8 IFNG IL2 IL6 TNF
50 11.73 IL6 TLR2 TLR4 TNF

GO Terms for Filariasis

Cellular components related to Filariasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 ALB CCL5 CHIT1 IFNG IL10 IL2
2 membrane raft GO:0045121 9.62 TLR1 TLR2 TLR6 TNF
3 external side of plasma membrane GO:0009897 9.55 CTLA4 IFNG IL6 TLR4 TNF
4 phagocytic vesicle membrane GO:0030670 9.54 TLR1 TLR2 TLR6
5 extracellular space GO:0005615 9.32 ALB CCL5 CHIT1 IFNG IL10 IL2
6 Toll-like receptor 1-Toll-like receptor 2 protein complex GO:0035354 9.26 TLR1 TLR2

Biological processes related to Filariasis according to GeneCards Suite gene sharing:

(show top 50) (show all 96)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.98 IL6 TLR2 TLR4 TLR9 TNF
2 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.97 IL10 IL5 IL6 TNF
3 response to virus GO:0009615 9.95 CCL5 IFNG TNF
4 cellular response to lipopolysaccharide GO:0071222 9.95 IFNG IL10 IL6 TLR4 TNF
5 response to glucocorticoid GO:0051384 9.93 IL10 IL6 TNF
6 defense response to Gram-positive bacterium GO:0050830 9.93 IL6 TLR2 TNF
7 positive regulation of T cell proliferation GO:0042102 9.93 CCL5 IFNG IL2 IL6
8 response to insulin GO:0032868 9.92 IL10 IL6 TLR2
9 regulation of insulin secretion GO:0050796 9.92 CCL5 IFNG TNF
10 positive regulation of JNK cascade GO:0046330 9.92 TLR4 TLR9 TNF
11 positive regulation of smooth muscle cell proliferation GO:0048661 9.91 CCL5 IL6 TNF
12 positive regulation of inflammatory response GO:0050729 9.91 IL2 TLR2 TLR4 TLR9
13 defense response to bacterium GO:0042742 9.91 IFNG IL10 TLR1 TLR4 TLR6 TLR9
14 humoral immune response GO:0006959 9.9 IFNG IL6 TNF
15 defense response to Gram-negative bacterium GO:0050829 9.9 IL6 TLR4 TLR9
16 positive regulation of cell adhesion GO:0045785 9.9 CCL5 IFNG TNF
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.9 CCL5 IFNG IL2 IL6
18 positive regulation of interferon-gamma production GO:0032729 9.89 IL2 TLR4 TNF
19 positive regulation of tumor necrosis factor production GO:0032760 9.89 IFNG TLR2 TLR4 TLR9
20 positive regulation of B cell proliferation GO:0030890 9.88 IL2 IL5 TLR4
21 positive regulation of JUN kinase activity GO:0043507 9.87 TLR6 TLR9 TNF
22 response to bacterium GO:0009617 9.86 CHIT1 IL6 TLR4
23 positive regulation of nitric oxide biosynthetic process GO:0045429 9.86 IFNG IL6 TLR4 TNF
24 positive regulation of interferon-beta production GO:0032728 9.85 TLR2 TLR4 TLR9
25 positive regulation of interleukin-10 production GO:0032733 9.84 TLR2 TLR4 TLR9
26 defense response to protozoan GO:0042832 9.83 IFNG IL10 IL6
27 positive regulation of JAK-STAT cascade GO:0046427 9.83 CCL5 IL5 IL6
28 negative regulation of growth of symbiont in host GO:0044130 9.83 IFNG IL10 TNF
29 lipopolysaccharide-mediated signaling pathway GO:0031663 9.83 CCL5 TLR2 TLR4 TNF
30 toll-like receptor signaling pathway GO:0002224 9.83 TLR1 TLR2 TLR4 TLR6 TLR9
31 cell activation GO:0001775 9.82 TLR1 TLR2 TLR6
32 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.82 TLR2 TLR4 TLR9
33 response to molecule of bacterial origin GO:0002237 9.81 IL10 TLR2 TLR9
34 positive regulation of interleukin-8 production GO:0032757 9.81 TLR2 TLR4 TLR9 TNF
35 I-kappaB phosphorylation GO:0007252 9.8 TLR2 TLR4 TLR9
36 negative regulation of interleukin-6 production GO:0032715 9.8 IL10 TLR4 TLR9 TNF
37 positive regulation of interleukin-6 production GO:0032755 9.8 IL6 TLR2 TLR4 TLR9 TNF
38 positive regulation of immunoglobulin secretion GO:0051024 9.79 IL2 IL5 IL6
39 positive regulation of interleukin-12 production GO:0032735 9.78 IFNG TLR2 TLR4 TLR9
40 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.77 IL10 TNF
41 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.77 IFNG TNF
42 negative regulation of B cell proliferation GO:0030889 9.77 CTLA4 IL10
43 cellular response to hepatocyte growth factor stimulus GO:0035729 9.77 IL10 IL6
44 microglial cell activation GO:0001774 9.77 TLR2 TLR6
45 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.77 IL10 TNF
46 positive regulation of podosome assembly GO:0071803 9.77 IL5 TNF
47 positive regulation of protein import into nucleus, translocation GO:0033160 9.76 IFNG IL6
48 T-helper 1 type immune response GO:0042088 9.76 TLR4 TLR6
49 negative regulation of interleukin-17 production GO:0032700 9.76 IFNG TLR4
50 positive regulation of tumor necrosis factor biosynthetic process GO:0042535 9.76 TLR1 TLR4

Molecular functions related to Filariasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 receptor activity GO:0004872 9.71 TLR1 TLR2 TLR4 TLR6
2 growth factor activity GO:0008083 9.62 IL10 IL2 IL5 IL6
3 transmembrane signaling receptor activity GO:0004888 9.55 TLR1 TLR2 TLR4 TLR6 TLR9
4 lipopolysaccharide receptor activity GO:0001875 9.37 TLR2 TLR4
5 Toll-like receptor 2 binding GO:0035663 9.26 TLR1 TLR6
6 cytokine activity GO:0005125 9.17 CCL5 IFNG IL10 IL2 IL5 IL6
7 lipopeptide binding GO:0071723 9.13 TLR1 TLR2 TLR6

Sources for Filariasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....